Based on the excellent druggability of SMUZ106, the aim of this study is to demonstrate the targeting and selectivity of SMUZ106 to EGFR and to investigate whether SMUZ106 can be used to overcome TMZ resistance, treating EGFRvIII overexpression in GBMs and effectively inhibiting the proliferation of GBM cells in vivo. This evidence concerns the gene EGFR and glioblastoma.